Maryn McKenna, writing tonight for CIDRAP, has an overview of some of the presentations delivered over the weekend at the ICAAC (Interscience Conference on Antimicrobial Agents and Chemotherapy) meeting in San Francisco.
Maryn McKenna Contributing Writer
Sep 14, 2009 (CIDRAP News) – A wide range of research findings on pandemic H1N1 influenza, seasonal flu, and avian flu was presented over the weekend at the 49th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco (www.icaac.org).
Triple antiviral therapy better than single drugs
A triple combination therapy comprising three flu antiviral drugs—amantadine, oseltamivir (Tamiflu), and ribavirin—controls replication of flu viruses better than any of those drugs used independently, according to a multi-national team. Researchers from Adamas Pharmaceuticals in California, Utah State University, the Naval Health Research Center of San Diego, the University of Alabama, and Amsterdam Medical Center in the Netherlands tested the drugs alone and in combination in vitro against H1N1 flu viruses and also against seasonal flu strains that were resistant to amantadine and oseltamivir. (Nguyen JT, et al: "In vitro activity of triple combination therapy against drug-resistant influenza viruses.")
In her report, Maryn also brings us briefs on the following subjects as well:
Rapid flu tests miss H1N1 cases
Link between immunoglobulin levels and H1N1 severity seen
MRSA as fatal complication in H1N1 cases
IV peramivir compares well with Tamiflu for seasonal flu
Oseltamivir improves survival in H5N1 and seasonal flu
H1N1 described as all-ages infection
Severe H1N1 cases in children
Other CIDRAP stories tonight include:
Novel H1N1 Flu Breaking News